A star drug in Mallinckrodt’s $1.2B Sucampo buyout flops in pivotal trial
Some of the insiders at Mallinckrodt $MNK may be wondering today why they paid $1.2 billion for Sucampo just 10 months ago. One of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
